CLINICAL TRIALS AND OBSERVATIONS A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia
نویسندگان
چکیده
1Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; 2Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea; 3Division of Hematology-Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea; 4Department of Internal Medicine, Daegu Catholic University Hospital, Daegu, Korea; 5Department of Internal Medicine, Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Korea; 6Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University, Anyang, Korea; 7Department of Internal Medicine, Daegu Fatima Hospital, Daegu, Korea; 8Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University, Jinju, Korea; 9Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea; and 10Cooperative Study Group A for Hematology, Seoul, Korea
منابع مشابه
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
The treatment of older patients with acute myeloid leukemia (AML) remains unsatisfactory, with complete remission (CR) achieved in only approximately 50% and long-term disease-free survival in 10% to 20%. Three hundred eighty-eight patients (60 years of age and older) with newly diagnosed de novo AML were randomly assigned to receive placebo (P) or granulocyte-macrophage colony-stimulating fact...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study
Shigeki Ohtake,1 Shuichi Miyawaki,2 Hiroyuki Fujita,3 Hitoshi Kiyoi,4 Katsuji Shinagawa,5 Noriko Usui,6 Hirokazu Okumura,7 Koichi Miyamura,8 Chiaki Nakaseko,9 Yasushi Miyazaki,10 Atsushi Fujieda,11 Tadashi Nagai,12 Takahisa Yamane,13 Masafumi Taniwaki,14 Masatomo Takahashi,15 Fumiharu Yagasaki,16 Yukihiko Kimura,17 Norio Asou,18 Hisashi Sakamaki,19 Hiroshi Handa,20 Sumihisa Honda,21 Kazunori Oh...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML
We conducted an open-label phase 1 study exploring the feasibility, safety, and biologic activity of epigenetic priming with decitabine before standard induction chemotherapy in patients with less-thanfavorable risk of acute myelogenous leukemia (AML). We directly compared the clinical and DNA-hypomethylating activity of decitabine delivered at 20 mg/m2 by either a 1-hour infusion (Arm A) or a ...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group
The optimal induction for older adults with acute myeloid leukemia (AML) is unknown. Several anthracyclines have been proposed, but the data remain equivocal. Additionally, few prospective trials of priming with hematopoietic growth factors to cycle leukemia cells prior to induction chemotherapy have been conducted. Three hundred and sixtytwo older adults with previously untreated AML were rand...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
In an attempt to improve induction chemotherapy for older patients with acute myeloid leukemia (AML),1314 patients were randomized to 1 of 3 induction treatments for 2 courses of DAT (daunorubicin, cytarabine, and thioguanine) 3 1 10, ADE (daunorubicin, cytarabine, and etoposide) 10 1 3 1 5, or MAC (mitoxantronecytarabine). The remission rate in the DAT arm was significantly better than ADE (62...
متن کامل